![Antonio Calles: Cardiotoxicity of osimertinib is real](https://oncodaily.com/pub/uploads/2025/02/Antonio-Calles-1280x720.jpg)
Antonio Calles/ruberinternacional.es
Feb 6, 2025, 15:29
Antonio Calles: Cardiotoxicity of osimertinib is real
Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared an article Minjung Bak and colleagues authored on X:
“Cardiotoxicity of osimertinib is real. In this Korean study, osimertinib-related cardiotoxicity was 4.7%, including 3.4% requiring cardiologic intervention. Age and previous heart conditions identified. Implications for long-lasting treatment.”
The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population
Authors: Minjung Bak et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 6, 2025, 15:29
Feb 6, 2025, 15:21
Feb 6, 2025, 15:13
Feb 6, 2025, 15:12
Feb 6, 2025, 15:11